Platelets in myelodysplastic syndrome are reduced to 0. Patients with this condition are at great risk of bleeding. Treatment measures mainly include: 1. Platelet transfusion to enhance platelet therapy is given, along with hemostatic drugs such as hemostatin and lidostat to prevent visceral bleeding, and TPO receptor agonists can also be used to stimulate hematopoietic platelet production. 2. For the primary myelodysplastic syndrome, drug therapy can be used. Drug therapy for this disease mainly includes immunomodulators, such as thalidomide and lenalidomide, which are effective for low-risk patients. In addition, the immunosuppressant cyclosporine can be used to treat the disease, and a class of demethylating drugs such as azacitidine and decitabine can be used for higher-risk patients.3. For patients with high primitive cells and generally good condition, low-dose chemotherapy combined with demethylating drugs can be given to treat the disease.4. For younger and higher-risk patients, allogeneic hematopoietic stem cell transplantation can be considered with a suitable donor, which is also the the only possible cure for this disease.